OverviewSuggest Edit

Sonnet BioTherapeutics is an oncology-focused biotechnology company. Its proprietary FHAB (Fully Human Albumin Binding) technology enables the development of targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB platform utilizes a human single-chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues.
HQPrinceton, US

Latest Updates

Employees (est.) (Apr 2020)30
Revenue (FY, 2019)$30.1 M(-25%)
Share Price (Nov 2020)$2.6
Cybersecurity ratingAMore

Key People/Management at Sonnet BioTherapeutics

Pankaj Mohan

Pankaj Mohan

Founder, CEO & Chairman
Jay Cross

Jay Cross

Chief Financial Officer
John K. Cini

John K. Cini

Chief Scientific Officer & Co-Founder
Terence Rugg

Terence Rugg

Chief Medical Officer
Susan Dexter

Susan Dexter

Chief Technical Officer
Show more

Sonnet BioTherapeutics Office Locations

Sonnet BioTherapeutics has an office in Princeton
Princeton, US (HQ)
100 Overlook Center
Show all (1)

Sonnet BioTherapeutics Financials and Metrics

Sonnet BioTherapeutics Revenue

Sonnet BioTherapeutics's revenue was reported to be $30.14 m in FY, 2019

Net income (Q3, 2020)


EBIT (Q3, 2020)


Market capitalization (27-Nov-2020)


Closing stock price (27-Nov-2020)


Cash (30-Jun-2020)



Sonnet BioTherapeutics's current market capitalization is $36.3 m.
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



General and administrative expense


Operating expense total


Depreciation and amortization

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020



General and administrative expense


R&D expense


Operating expense total

USDQ2, 2011

Financial Leverage

1.7 x
Show all financial metrics

Sonnet BioTherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Sonnet BioTherapeutics Online and Social Media Presence

Embed Graph

Sonnet BioTherapeutics News and Updates

Thinking about buying stock in Sonnet BioTherapeutics, CHF Solutions, Harmonic Inc, Tiziana Life Sciences, or Seanergy Maritime Holdings?

NEW YORK, Aug. 4, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONN, CHFS, HLIT, TLSA, and SHIP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Sonnet BioTherapeutics Frequently Asked Questions

  • When was Sonnet BioTherapeutics founded?

    Sonnet BioTherapeutics was founded in 2011.

  • Who are Sonnet BioTherapeutics key executives?

    Sonnet BioTherapeutics's key executives are Pankaj Mohan, Jay Cross and John K. Cini.

  • How many employees does Sonnet BioTherapeutics have?

    Sonnet BioTherapeutics has 30 employees.

  • What is Sonnet BioTherapeutics revenue?

    Latest Sonnet BioTherapeutics annual revenue is $30.1 m.

  • What is Sonnet BioTherapeutics revenue per employee?

    Latest Sonnet BioTherapeutics revenue per employee is $1 m.

  • Who are Sonnet BioTherapeutics competitors?

    Competitors of Sonnet BioTherapeutics include 7 Hills Pharma, Arcellx and IDP Pharma.

  • Where is Sonnet BioTherapeutics headquarters?

    Sonnet BioTherapeutics headquarters is located at 100 Overlook Center, Princeton.

  • Where are Sonnet BioTherapeutics offices?

    Sonnet BioTherapeutics has an office in Princeton.

  • How many offices does Sonnet BioTherapeutics have?

    Sonnet BioTherapeutics has 1 office.